Yes, GLP-1 receptor agonists can be used at GFR 25
Most GLP-1 receptor agonists (dulaglutide, liraglutide, and semaglutide) require no dose adjustment at GFR 25 mL/min/1.73 m² and are recommended for patients with type 2 diabetes and advanced CKD. 1
Specific Agent Recommendations at GFR 25
Preferred Agents (No Dose Adjustment Required)
- Dulaglutide: No dose adjustment needed at any level of kidney function 1
- Liraglutide: No dose adjustment needed at any level of kidney function 1
- Semaglutide (injectable and oral): No dose adjustment needed at any level of kidney function 1
These three agents have demonstrated cardiovascular benefits in large outcome trials and are the preferred choices 1.
Agents to Avoid at GFR 25
- Exenatide: Use not recommended at GFR 15-29 mL/min/1.73 m² (Stage 4 CKD) 1
- Lixisenatide: Use not recommended at GFR 15-29 mL/min/1.73 m² (Stage 4 CKD) 1
Clinical Evidence Supporting Use
GLP-1 receptor agonists provide significant cardiorenal benefits even in advanced CKD. The 2022 ADA/KDIGO consensus specifically recommends adding a long-acting GLP-1 receptor agonist for patients not achieving glycemic targets despite metformin and/or SGLT2 inhibitor therapy 1.
Clinical trials have included patients with eGFR as low as 15 mL/min/1.73 m², demonstrating:
- Reduced albuminuria and slower eGFR decline 1
- Greater MACE risk reduction in patients with eGFR <60 compared to those with eGFR ≥60 1
- Maintained cardiovascular and kidney benefits across all stages of CKD 2, 3
Important Monitoring Considerations
Monitor for gastrointestinal side effects and changes in kidney function when initiating or escalating doses 4. At GFR 25:
- Start with the lowest dose and titrate slowly to minimize GI side effects
- Monitor eGFR when initiating therapy or with severe GI reactions (nausea, vomiting, diarrhea can worsen kidney function through volume depletion) 4
- These agents are metabolized primarily through proteolytic degradation, not kidney excretion, making them safe in advanced CKD 4
Practical Algorithm
At GFR 25 mL/min/1.73 m²:
- First choice: Dulaglutide, liraglutide, or semaglutide (prioritize agents with CV outcome data) 1, 5
- Avoid: Exenatide and lixisenatide 1
- Start low, go slow: Use lowest starting dose and titrate gradually over weeks 5
- Monitor: Check eGFR within 2-4 weeks after initiation, then regularly 4
- Continue therapy: Can be maintained even as eGFR declines further, unless not tolerated 5
Common Pitfalls to Avoid
- Don't avoid GLP-1 RAs due to kidney function alone at GFR 25—the preferred agents are safe and beneficial 1
- Don't use exenatide or lixisenatide at this level of kidney function 1
- Don't skip dose titration—rapid escalation increases GI side effects, which can lead to volume depletion and acute kidney injury 4
- Don't combine with DPP-4 inhibitors—no added benefit and redundant mechanism 6